US$ 24.90
pharma news today obesity drugs glp-1 Chart: 1 in 8 Americans Now Use for Weight Loss GLP-1 Antagonists Increase Plan Drug
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 32

Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al
The deal was made in connection with Novo Holdings acquisition of the drug manufacturing company Catalent (CTLT)

ADA Recommendations for GLP-1 RA in T2DM Patients The GLP-1 receptor agonists, with or without metformin based on glycemic needs, are appropriate initial therapy for patients with type 2 diabetes mellitus (T2DM) with or at high risk for atherosclerotic cardiovascular disease (ASCVD)/indicators of high-risk, heart failure (HF), or chronic kidney disease (CKD)

This is critical for treating weight loss and metabolic disease, where success depends not only on the target but how its delivered
Deposits should land quickly, with clear minimums and accurate timelines